Impact of patents on Indian pharma industry's growth and competency: A viewpoint of pharmaceutical companies in India

Manthan D. Janodia, J. Venkata Rao, Sureshwar Pandey, D. Sreedhar, Virendra S. Ligade, N. Udupa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Instruments of intellectual property rights (IPR) are considered to achieve economic, social and technological advancement for a country in all aspects. Of all the instruments of IPR, patent is the most contentious issue which is deliberated in several international fora. Patents are mostly debated for their role in pharmaceutical field. India signed General Agreement on Tariffs and Trade (GATT) in 1994 agreeing to implement the IPR in all fields of technology, including product patent, with effect from 1 January 1995. Taking into account India's status as a developing country, India was granted a transition period of ten years from 1995 to 2005 to switch over from process patent to product patent. With this shift, it was imperative for Indian pharmaceutical companies to embrace product patents. This study was undertaken with the objective of identifying the situation in India after product patent regime was implemented. The role of Indian pharmaceutical companies in the era of product patent is crucial. The authors attempted to identify how Indian pharmaceutical companies view product patent regime, hindering the growth of industry or providing impetus to R&D, in this study. The measures taken by these companies to survive and grow in product patent regime have also been analysed.

Original languageEnglish
Pages (from-to)432-436
Number of pages5
JournalJournal of Intellectual Property Rights
Volume14
Issue number5
Publication statusPublished - 09-2009

Fingerprint

pharmaceutical
patent
India
industry
intellectual property
right of ownership
regime
GATT
developing country

All Science Journal Classification (ASJC) codes

  • Law

Cite this

@article{44e1009aea834eed83923696afed975d,
title = "Impact of patents on Indian pharma industry's growth and competency: A viewpoint of pharmaceutical companies in India",
abstract = "Instruments of intellectual property rights (IPR) are considered to achieve economic, social and technological advancement for a country in all aspects. Of all the instruments of IPR, patent is the most contentious issue which is deliberated in several international fora. Patents are mostly debated for their role in pharmaceutical field. India signed General Agreement on Tariffs and Trade (GATT) in 1994 agreeing to implement the IPR in all fields of technology, including product patent, with effect from 1 January 1995. Taking into account India's status as a developing country, India was granted a transition period of ten years from 1995 to 2005 to switch over from process patent to product patent. With this shift, it was imperative for Indian pharmaceutical companies to embrace product patents. This study was undertaken with the objective of identifying the situation in India after product patent regime was implemented. The role of Indian pharmaceutical companies in the era of product patent is crucial. The authors attempted to identify how Indian pharmaceutical companies view product patent regime, hindering the growth of industry or providing impetus to R&D, in this study. The measures taken by these companies to survive and grow in product patent regime have also been analysed.",
author = "Janodia, {Manthan D.} and Rao, {J. Venkata} and Sureshwar Pandey and D. Sreedhar and Ligade, {Virendra S.} and N. Udupa",
note = "Cited By :5 Export Date: 10 November 2017 Correspondence Address: Janodia, M. D.; Manipal College of Pharmaceutical Sciences, Manipal University, Manipal 576 104, India; email: mdjanodia1978@yahoo.co.in References: Malhotra, N.K., (2001) Marketing Research, an Applied Orientation, , (Pearson Education, Singapore), First Indian reprint; Boyd, H., Basic methods of collecting data (2000) Marketing Research Text and Cases, , edited by H W Boyd, R Westfall and S Stasch (Richard Irwin Inc, Illinois); Tull, D., The sampling process (1999) Marketing Research Measurement and Method, , edited by D S Tull and D I Hawkins (Macmillan Publishing Company, New York); Aaker, D., Fundamental of data analysis (2001) Marketing Research, , edited by D Aaker, V Kumar and G Day (John Wiley & Sons, Canada); Chaudhuri, S., Is product patent protection necessary in developing countries for innovation? (2008) Presented in Conference on R&D by Indian Pharmaceutical Companies after TRIPS, , http://www.iprsonline.org/resources/docs/Sudip-WP-India-R&D-TRIPS- Sept-007.pdf, Indian Institute of Management, Kolkata, WPS No. 614/ September 2007, 16, 21 May; (2008), www1.imshealth.com, World Pharmaceutical Market Summary, Sales through Retail PharmaciesUR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951843430&partnerID=40&md5=8aa3c7f2421b39edc4e2c87801e9b707",
year = "2009",
month = "9",
language = "English",
volume = "14",
pages = "432--436",
journal = "Journal of Intellectual Property Rights",
issn = "0971-7544",
publisher = "National Institute of Science Communication and Information Resources (NISCAIR)",
number = "5",

}

TY - JOUR

T1 - Impact of patents on Indian pharma industry's growth and competency: A viewpoint of pharmaceutical companies in India

AU - Janodia, Manthan D.

AU - Rao, J. Venkata

AU - Pandey, Sureshwar

AU - Sreedhar, D.

AU - Ligade, Virendra S.

AU - Udupa, N.

N1 - Cited By :5 Export Date: 10 November 2017 Correspondence Address: Janodia, M. D.; Manipal College of Pharmaceutical Sciences, Manipal University, Manipal 576 104, India; email: mdjanodia1978@yahoo.co.in References: Malhotra, N.K., (2001) Marketing Research, an Applied Orientation, , (Pearson Education, Singapore), First Indian reprint; Boyd, H., Basic methods of collecting data (2000) Marketing Research Text and Cases, , edited by H W Boyd, R Westfall and S Stasch (Richard Irwin Inc, Illinois); Tull, D., The sampling process (1999) Marketing Research Measurement and Method, , edited by D S Tull and D I Hawkins (Macmillan Publishing Company, New York); Aaker, D., Fundamental of data analysis (2001) Marketing Research, , edited by D Aaker, V Kumar and G Day (John Wiley & Sons, Canada); Chaudhuri, S., Is product patent protection necessary in developing countries for innovation? (2008) Presented in Conference on R&D by Indian Pharmaceutical Companies after TRIPS, , http://www.iprsonline.org/resources/docs/Sudip-WP-India-R&D-TRIPS- Sept-007.pdf, Indian Institute of Management, Kolkata, WPS No. 614/ September 2007, 16, 21 May; (2008), www1.imshealth.com, World Pharmaceutical Market Summary, Sales through Retail PharmaciesUR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951843430&partnerID=40&md5=8aa3c7f2421b39edc4e2c87801e9b707

PY - 2009/9

Y1 - 2009/9

N2 - Instruments of intellectual property rights (IPR) are considered to achieve economic, social and technological advancement for a country in all aspects. Of all the instruments of IPR, patent is the most contentious issue which is deliberated in several international fora. Patents are mostly debated for their role in pharmaceutical field. India signed General Agreement on Tariffs and Trade (GATT) in 1994 agreeing to implement the IPR in all fields of technology, including product patent, with effect from 1 January 1995. Taking into account India's status as a developing country, India was granted a transition period of ten years from 1995 to 2005 to switch over from process patent to product patent. With this shift, it was imperative for Indian pharmaceutical companies to embrace product patents. This study was undertaken with the objective of identifying the situation in India after product patent regime was implemented. The role of Indian pharmaceutical companies in the era of product patent is crucial. The authors attempted to identify how Indian pharmaceutical companies view product patent regime, hindering the growth of industry or providing impetus to R&D, in this study. The measures taken by these companies to survive and grow in product patent regime have also been analysed.

AB - Instruments of intellectual property rights (IPR) are considered to achieve economic, social and technological advancement for a country in all aspects. Of all the instruments of IPR, patent is the most contentious issue which is deliberated in several international fora. Patents are mostly debated for their role in pharmaceutical field. India signed General Agreement on Tariffs and Trade (GATT) in 1994 agreeing to implement the IPR in all fields of technology, including product patent, with effect from 1 January 1995. Taking into account India's status as a developing country, India was granted a transition period of ten years from 1995 to 2005 to switch over from process patent to product patent. With this shift, it was imperative for Indian pharmaceutical companies to embrace product patents. This study was undertaken with the objective of identifying the situation in India after product patent regime was implemented. The role of Indian pharmaceutical companies in the era of product patent is crucial. The authors attempted to identify how Indian pharmaceutical companies view product patent regime, hindering the growth of industry or providing impetus to R&D, in this study. The measures taken by these companies to survive and grow in product patent regime have also been analysed.

UR - http://www.scopus.com/inward/record.url?scp=77951843430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951843430&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77951843430

VL - 14

SP - 432

EP - 436

JO - Journal of Intellectual Property Rights

JF - Journal of Intellectual Property Rights

SN - 0971-7544

IS - 5

ER -